Viyash Scientific logo

Viyash Scientific CEO, MD, chairman, board of directors and AGM

NSE: VIYASHBSE: 512529Pharmaceuticals & BiotechnologySmall Cap

Formerly Sequent Scientific
Last close ₹204.18down ₹3.81 (1.83%)BSE ₹203.45

Share price at the NSE close on 23 Oct 2026. Previous close ₹207.99.

52-week range of traded prices to 23 Oct 2026
₹178.13Low, 23 Mar 2026₹298.00High, 6 Jul 2026
Market cap
₹9,017 Cr598th largest listed
P/E
Earlier quarters restated in the year
P/B
3.1
Dividend yield
Nonein the last 12 months
ROCE
11.2%
Debt to equity
0.14
Volume, NSE
44,68,18350.3% delivered

Viyash Scientific board of directors

At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares

  • Managing director and CEOHaribabu Bodepudi
  • ChairpersonKamal Kishore Sharma
  • Company Secretary and Compliance OfficerYOSHITA VORA

9 directors3 independent3 executive3 non-executive

  • Haribabu Bodepudi · Managing director and CEOExecutive · joined Aug 2023 · reappointed Dec 2025 · 1 listed board · 1 committee seat
  • Kamal Kishore Sharma · ChairpersonIndependent · joined Aug 2020 · reappointed Aug 2025 · 70 months as independent · 1 listed board · 1 as independent · 1 committee seat
  • Milind Shripad SarwateIndependent · joined Aug 2020 · reappointed Aug 2025 · 70 months as independent · 5 listed boards · 5 as independent · 7 committee seats, 4 as chair
  • Revati Parag KastureIndependent · joined Dec 2024 · reappointed Dec 2024 · 18 months as independent · 1 listed board · 1 as independent · 2 committee seats, 1 as chair
  • Rajaram NarayananExecutive · joined Apr 2022 · reappointed Dec 2025 · 1 listed board · 1 committee seat
  • Srinivas VasireddyExecutive · joined Dec 2025 · 1 listed board
  • Anuj Vishnukumar PoddarNon-executive · joined Sep 2025 · 1 listed board · 1 committee seat
  • Amit JainNon-executive · joined Apr 2026 · 2 listed boards · 1 committee seat
  • Abhiroop JayanthiNon-executive · joined Apr 2026 · 1 listed board

An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.

5 directors who left
  • Gregory John Andrews, left 30 Mar 2026: Others
  • Fabian Martin Kausche, left 30 Mar 2026: Others
  • Vedprakash Shantalingappa Ragate, left 30 Sep 2025: Others
  • Neeraj Bharadwaj, left 5 Sep 2025: Others
  • Kausalya Santhanam, left 27 Oct 2024: Tenure Completion

Committees and meetings

Who sits on each, and how often they met.Board meeting notices and outcomes

  • Board

    • 8 Jun 20268 of 9 present3 independent · 19 days in between
    • 19 May 20268 of 9 present3 independent · 26 days in between
    • 22 Apr 20269 of 9 present3 independent · 75 days in between
    • 5 Feb 20269 of 9 present3 independent

  • Audit Committee

    Chair Milind Shripad Sarwate

    Kamal Kishore Sharma, Revati Parag Kasture, Anuj Vishnukumar Poddar

    • 19 May 20263 of 4 present3 independent · 49 days in between
    • 30 Mar 20264 of 4 present3 independent · 19 days in between
    • 10 Mar 20264 of 4 present3 independent · 32 days in between
    • 5 Feb 20264 of 4 present3 independent

  • Nomination and remuneration committee

    Chair Milind Shripad Sarwate

    Kamal Kishore Sharma, Anuj Vishnukumar Poddar

    • 19 May 20262 of 3 present2 independent · 26 days in between
    • 22 Apr 20263 of 3 present2 independent · 75 days in between
    • 5 Feb 20263 of 3 present2 independent

  • Stakeholders Relationship Committee

    Chair Revati Parag Kasture

    Milind Shripad Sarwate, Rajaram Narayanan, Haribabu Bodepudi

    • 30 Mar 20264 of 4 present2 independent

  • Risk Management Committee

    Chair Anuj Vishnukumar Poddar

    Milind Shripad Sarwate, Rajaram Narayanan, Haribabu Bodepudi, Revati Parag Kasture, Ramakant Singani

    • 30 Mar 20265 of 5 present2 independent

  • Corporate Social Responsibility Committee

    Chair Kamal Kishore Sharma

    Rajaram Narayanan, Haribabu Bodepudi

    • 19 May 20263 of 3 present1 independent · 49 days in between

Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.

Statutory auditor

Named in the results for the quarter to Jun 2026.

  • SRBC & Co. LLPPeer-review certificate valid to Feb 2029

A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.

Viyash Scientific AGM and shareholder votes

Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Viyash Scientific dividend history

Annual general meeting, 11 Aug 2026

1,33,984 shareholders on the register on 4 Aug 2026; present: 0 promoters and 60 others; votes counted by Nishant Darak / Nishant Darak and Associates.The company's voting result (opens in a new tab)

  1. Adoption of Audited Financial Statements of the Company for the financial year ended March 31, 2026
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 72.58% · promoters 100.00% · institutions 61.87% · other public 21.08%

  2. Re-appointment of Director-Dr. Haribabu Bodepudi
    Ordinary
    99.86% for0.14% against

    Against: promoters 0.00% · institutions 2.03% · other public 0.01%

    Turnout: all 69.16% · promoters 100.00% · institutions 62.01% · other public 10.04%

  3. Re-appointment of Director-Mr. Rajaram Narayanan
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 72.59% · promoters 100.00% · institutions 62.01% · other public 21.08%

  4. Ratification of revised remuneration payable to the Cost Auditor for the Financial Year 2025-2026
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 72.59% · promoters 100.00% · institutions 62.01% · other public 21.08%

  5. Ratification of remuneration payable to the Cost Auditor for the Financial Year 2026-2027
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 72.59% · promoters 100.00% · institutions 62.01% · other public 21.08%

  6. Adoption of a new set of Articles of Association of the Company
    Special
    97.99% for2.01% against

    Against: promoters 0.00% · institutions 30.79% · other public 0.01%

    Turnout: all 72.59% · promoters 100.00% · institutions 62.01% · other public 21.09%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 28 Jun 2026, 3 resolutions

1,24,825 shareholders on the register on 22 May 2026; votes counted by Nishant Darak / Nishant Darak and Associates.The company's voting result (opens in a new tab)

  1. Appointment of Mr. Amit Jain (DIN: 06917608) as a Non-Executive, Non-Independent Director, of the Company
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.05%

    Turnout: all 71.06% · promoters 100.00% · institutions 86.59% · other public 2.38%

  2. Appointment of Mr. Abhiroop Jayanthi (DIN: 10354445) as a Non-Executive, Non-Independent Director, of the Company
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.04%

    Turnout: all 71.06% · promoters 100.00% · institutions 86.59% · other public 2.38%

  3. To consider and approve one-time performance incentive to Mr. Rajaram Narayanan (DIN: 02977405), Whole-time Director & CEO-Animal Health
    Special
    98.79% for1.21% against

    Against: promoters 0.00% · institutions 8.61% · other public 11.23%

    Turnout: all 71.06% · promoters 100.00% · institutions 86.59% · other public 2.38%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 12 Mar 2026, 4 resolutions

1,33,361 shareholders on the register on 6 Feb 2026; votes counted by Nishant Darak / Nishant Darak and Associates.The company's voting result (opens in a new tab)

  1. Appointment and remuneration of Dr. Haribabu Bodepudi (DIN: 01119687) as Managing Director and Group CEO of the Company for a period of two years.
    Special
    97.32% for2.68% against

    Against: promoters 0.00% · institutions 25.39% · other public 0.04%

    Turnout: all 74.80% · promoters 100.00% · institutions 74.52% · other public 19.87%

  2. Grant of options of more than 1 (one per cent) of the issued capital of the Company to an identified employee in 1 year.
    Special
    97.32% for2.68% against

    Against: promoters 0.00% · institutions 25.39% · other public 0.12%

    Turnout: all 74.80% · promoters 100.00% · institutions 74.52% · other public 19.87%

  3. Appointment of Mr. Rajaram Narayanan (DIN: 02977405) as a Whole-time Director.
    Special
    98.83% for1.17% against

    Against: promoters 0.00% · institutions 11.74% · other public 0.01%

    Turnout: all 78.92% · promoters 100.00% · institutions 74.52% · other public 34.55%

  4. Appointment of Mr. Srinivas Vasireddy (DIN: 09771153) as Whole time Director (Executive) of the Company for a period of two years.
    Special
    98.64% for1.36% against

    Against: promoters 0.00% · institutions 13.65% · other public 0.01%

    Turnout: all 79.34% · promoters 100.00% · institutions 74.52% · other public 36.02%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

How mutual funds voted

Fund houses must disclose how they vote at every meeting of a company they hold.Funds that hold it

Mutual fund votes, meeting of 11 Aug 2026, 1 fund house so far (houses' deadline to file 15 Oct 2026)

  • Adoption of Audited Financial Statements of the Company for the financial year ended March 31, 2026
    1 for0 against
  • Re-appointment of Director-Dr. Haribabu Bodepudi
    Against Angel One Mutual Fund
    • Angel One Mutual FundGovernance & Transparency concern: Excessive remuneration; Ambiguity over paid remuneration components.
    0 for1 against
  • Re-appointment of Director-Mr. Rajaram Narayanan
    1 for0 against
  • Ratification of revised remuneration payable to the Cost Auditor for the Financial Year 2025-2026
    1 for0 against
  • Ratification of remuneration payable to the Cost Auditor for the Financial Year 2026-2027
    1 for0 against
  • Adoption of a new set of Articles of Association of the Company
    Against Angel One Mutual Fund
    • Angel One Mutual FundGovernance & Transparency Concern: Proposed AoA not disclosed / cannot be located.
    0 for1 against

Mutual fund votes, meeting of 28 Jun 2026, 7 fund houses

  • Appointment of Mr. Amit Jain (DIN: 06917608) as a Non-Executive, Non-Independent Director, of the Company
    7 for0 against
  • Appointment of Mr. Abhiroop Jayanthi (DIN: 10354445) as a Non-Executive, Non-Independent Director, of the Company
    7 for0 against
  • To consider and approve one-time performance incentive to Mr. Rajaram Narayanan (DIN: 02977405), Whole-time Director & CEO-Animal Health
    7 for0 against
6 earlier meetings

Mutual fund votes, meeting of 12 Mar 2026, 7 fund houses

  • Appointment and remuneration of Dr. Haribabu Bodepudi (DIN: 01119687) as Managing Director and Group CEO of the Company for a period of two years.
    Against Angel One Mutual Fund, Bandhan Mutual Fund, Groww Mutual Fund, Mirae Asset Mutual Fund, Motilal Oswal Mutual Fund, UTI Mutual Fund
    • Angel One Mutual FundGovernance concern: The remuneration proposed to be paid to Mr. Haribabu Bodepudi appears excessive when compared with the Company’s performance.
    • Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual FundCompliant with law. Governance concern: The remuneration proposed to be paid to Mr. Haribabu Bodepudi appears excessive when compared with the Company’s performance.
    • Mirae Asset Mutual FundAs per advisory recommendation (Passive holding)
    • UTI Mutual FundDr. Haribabu Bodepudi, 61, was the founder and Chief Executive Officer of Viyash Life Sciences Private Limited, prior to its merger with Sequent Scientific Limited. Following the completion of the merger, the board has appointed Dr. Haribabu Bodepudi as Managing Director and Group Chief Executive Officer (Group CEO) for two years from 16 December 2025. We approve his re-appointment, However in terms of remuneration, there is no clarity regarding the exercise price and the performance criteria. Therefore, we do not support the resolution.
    1 for6 against
  • Grant of options of more than 1 (one per cent) of the issued capital of the Company to an identified employee in 1 year.
    Against Angel One Mutual Fund, Bandhan Mutual Fund, Groww Mutual Fund, Mirae Asset Mutual Fund, Motilal Oswal Mutual Fund, UTI Mutual Fund
    • Angel One Mutual FundGovernance concern: Mr. Bodepudi is proposed to be granted ~71% of the total ESOP Pool. The Company has not provided sufficient justification for allocating such a significant portion of the pool to a single individual. Further, the maximum potential economic benefit arising from the proposed grant appears excessive.
    • Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual FundCompliant with law. Governance concern: Mr. Bodepudi is proposed to be granted ~71% of the total ESOP Pool. The Company has not provided sufficient justification for allocating such a significant portion of the pool to a single individual. Further, the maximum potential economic benefit arising from the proposed grant appears excessive.
    • Mirae Asset Mutual FundAs per advisory recommendation (Passive holding)
    • UTI Mutual FundThrough a separate resolution, the company is seeking shareholders’ approval to issue stock options in excess of 1% of the issued capital under the Viyash ESOP 2026. The company proposes to grant up to 9.6 mn options under the ESOP 2026 to Dr. Hari Bodepudi, this represents 71.5% of the scheme size. However, there is no clarity regarding the exercise price and performance criteria of the ESOP grant. Therefore, we do not support the resolution.
    1 for6 against
  • Appointment of Mr. Rajaram Narayanan (DIN: 02977405) as a Whole-time Director.
    7 for0 against
  • Appointment of Mr. Srinivas Vasireddy (DIN: 09771153) as Whole time Director (Executive) of the Company for a period of two years.
    Against Angel One Mutual Fund, Bandhan Mutual Fund, Groww Mutual Fund, Mirae Asset Mutual Fund, Motilal Oswal Mutual Fund, UTI Mutual Fund
    • Angel One Mutual FundGovernance and Transparency Concern: The Company has not disclosed the number of options proposed to be granted, nor has it prescribed an upper limit on the potential ESOP grants that may be made to proposed director in the future. In the absence of such disclosure, shareholders are unable to meaningfully assess the potential economic benefit that may accrue to him pursuant to the future ESOP grant.
    • Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual FundCompliant with law. No concern w.r.t quantum of proposed remuneration per se. Governance and Transparency Concern: The Company has not disclosed the number of options proposed to be granted, nor has it prescribed an upper limit on the potential ESOP grants that may be made to proposed director in the future. In the absence of such disclosure, shareholders are unable to meaningfully assess the potential economic benefit that may accrue to him pursuant to the future ESOP grant.
    • Mirae Asset Mutual FundAs per advisory recommendation (Passive holding)
    • UTI Mutual FundSrinivas Vasireddy, 57, was associated with Viyash Lifesciences Private Limited, where he oversaw overall API operations across its units. Prior to this, he served as the Head - API (Special Projects) at Mylan Laboratories. He has over 37 years of experience across all facets of API operations. The company proposes to appoint his as Whole-time Director for two years from 16 December 2025. We support his appointment. However, there is no clarity on the quantum of ESOPs, exercise price and Performance criteria for the options that Srinivas Vasireddy is entitled to receive during his tenure. Hence, we do not support the resolution.
    1 for6 against

Mutual fund votes, meeting of 28 Dec 2025, 7 fund houses

  • 1. Approval for change the name of the Company from Sequent Scientific Limited to Viyash Scientific Limited, and the consequent alteration in the Memorandum of Association and Articles of Association of the Company.MoreLess
    1 for0 against
  • 2. Approval for the alteration of the Objects Clause of the Memorandum of Association of the Company.
    1 for0 against
  • Approval for change the name of the Company from Sequent Scientific Limited to Viyash Scientific Limited, and the consequent alteration in the Memorandum of Association and Articles of Association of the Company.MoreLess
    5 for0 against
  • Approval for the alteration of the Objects Clause of the Memorandum of Association of the Company.
    5 for0 against
  • Approve alteration to the Object Clause of the Memorandum of Association (MoA)
    1 for0 against
  • Approve change in name of the company to ‘Viyash Scientific Limited’ from ‘Sequent Scientific Limited’ and consequent amendment to the Memorandum of Association (MoA) and the Articles of Association (AoA)MoreLess
    1 for0 against

Mutual fund votes, meeting of 2 Nov 2025, 8 fund houses

  • 1. Approval for the appointment of Mr. Anuj Poddar (DIN: 01908009) as a Non-Executive Director of the Company, liable to retire by rotation, with effect from September 5, 2025.
    1 for0 against
  • Appoint Anuj Poddar (DIN: 01908009) as Non-Executive Non-Independent Director from 5 September 2025, liable to retire by rotation
    1 for0 against
  • Approval for the appointment of Mr. Anuj Poddar (DIN: 01908009) as a Non-Executive Director of the Company, liable to retire by rotation, with effect from September 5, 2025.
    6 for0 against

Mutual fund votes, meeting of 30 Aug 2025, 7 fund houses

  • 1. Scheme of Amalgamation amongst Sequent Scientific Limited (Company or Applicant Company 1 or Amalgamated Company), Symed Labs Limited (Applicant Company 2 or Transferor Company 1), Vandana Life Sciences Private Limited (Applicant Company 3 or Transferor Company 2), Appcure Labs Private Limited (Applicant Company 4 or Transferor Company 3), Vindhya Pharma (India) Private Limited (Applicant Company 5 or Transferor Company 4), S.V. Labs Private Limited (Applicant Company 6 or Transferor Company 5), Vindhya Organics Private Limited (Applicant Company 7 or Transferor Company 6), Viyash Life Sciences Private Limited (Applicant Company 8 or Transferee Company 1 or Amalgamating Company 1), Geninn Life Sciences Private Limited (Applicant Company 9 or Transferee Company 2 or Transferor Company 7), Sequent Research Limited (Applicant Company 10 or Amalgamating Company 2) and their respective shareholders and creditors.MoreLess
    1 for0 against
  • Approve scheme of arrangement for of Viyash Life Sciences Private Limited (Viyash) and its various subsidiaries, including Symed Labs Limited, Appcure Labs Pvt Ltd, Vindhya Pharma (India) Private Limited, Vandana Life Sciences Private Limited, SV Labs Private Limited, Geninn Life Sciences Private Limited and Vindhya Organics Private Limited along with Sequent Research Ltd (a wholly owned subsidiary of Sequent Scientific Limited (Sequent), with Sequent being the ultimate surviving entityMoreLess
    1 for0 against
  • Scheme of Amalgamation amongst Sequent Scientific Limited (Company or Applicant Company 1 or Amalgamated Company), Symed Labs Limited (Applicant Company 2 or Transferor Company 1), Vandana Life Sciences Private Limited (Applicant Company 3 or Transferor Company 2), Appcure Labs Private Limited (Applicant Company 4 or Transferor Company 3), Vindhya Pharma (India) Private Limited (Applicant Company 5 or Transferor Company 4), S.V. Labs Private Limited (Applicant Company 6 or Transferor Company 5), Vindhya Organics Private Limited (Applicant Company 7 or Transferor Company 6), Viyash Life Sciences Private Limited (Applicant Company 8 or Transferee Company 1 or Amalgamating Company 1), Geninn Life Sciences Private Limited (Applicant Company 9 or Transferee Company 2 or Transferor Company 7), Sequent Research Limited (Applicant Company 10 or Amalgamating Company 2) and their respective shareholders and creditors.MoreLess
    Against Angel One Mutual Fund, Bandhan Mutual Fund, Groww Mutual Fund
    • Angel One Mutual FundGovernance concern: While the multiples look directionally sensible, the Company should explain as to why the proposed valuation is fair and reasonable despite prima-facie there appearing to be a significant gap in certain multiples. Also, the Company should address the debt-related details of the entities involved for a holistic understanding of the entire transaction. Further, warrants to be issued against exchange with old warrants are valued at par with equity.
    • Bandhan Mutual Fund, Groww Mutual FundCompliant with law. Governance concern: While the multiples look directionally sensible, the Company should explain as to why the proposed valuation is fair and reasonable despite prima-facie there appearing to be a significant gap in certain multiples. Also, the Company should address the debt-related details of the entities involved for a holistic understanding of the entire transaction. Further, warrants to be issued against exchange with old warrants are valued at par with equity
    2 for3 against

Mutual fund votes, meeting of 8 Aug 2025, 7 fund houses

  • 1. To receive, consider, approve and adopt:_x000D_ a) The Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2025, together with the reports of Board of Directors and Auditors thereon and_x000D_ b) The Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2025, and the report of the Auditors thereon.MoreLess
    1 for0 against
  • 2. To re-appoint Mr. Rajaram Narayanan (DIN: 02977405), Managing Director and Chief Executive Officer who retires by rotation and being eligible, offers himself for re-appointment.
    1 for0 against
  • 3. To re-appoint Mr. Neeraj Bharadwaj (DIN: 01314963), Non-Executive Director who retires by rotation and being eligible, offers himself for re-appointment.
    1 for0 against
  • 4. Ratification of remuneration of Rs. 1,50,000 plus applicable tax and re-imbursement of out-of-pocket expenses payable to M/s. Joshi Apte and Associates, Practicing Cost Accountants, (Firm Registration Number: 000240) who was appointed by the Board of Directors of the Company to conduct the audit of the cost records of the Company for the financial year ending March 31, 2026.MoreLess
    1 for0 against
  • 5. Appointment of M/s BMP and Co. LLP , Practicing Company Secretaries (Firm Registration Number: L2017KR003200) as Secretarial Auditors of the Company, for a term of five (5) consecutive years, to hold office of the Secretarial Auditor for the Financial Year 2025-26 up to Financial Year 2029-30, on such remuneration, as may be mutually agreed between the Board of Directors of the Company and the Secretarial Auditors, from time to time.MoreLess
    1 for0 against
  • 6. To pay remuneration by way of commission to Non-Executive Directors (including Independent Directors) notwithstanding the profits / absence of profits / inadequacy of profits in the Company and such commission be paid to the said Non-Executive Directors (including Independent Directors) of the Company in such amounts or proportions and in such manner as may be determined by the Board of Directors of the Company for a period of three Financial Years i.e. FY 2025-26 to FY 2027-28 or such other time period as may be permitted under the Act.MoreLess
    Against quant Mutual Fund
    • quant Mutual FundRelated to the payment of commission to non-executive directors (including independent directors). Compliant with the law. Governance & transparency concern: Lack of absolute cap on proposed payment of commission & past data is insufficient.
    0 for1 against
  • 7. Payment of remuneration to Mr. Rajaram Narayanan (DIN: 02977405) as Managing Director and CEO of the Company for the period starting from April 1, 2025 to April 10, 2027.
    1 for0 against
  • 8. Re-appointment of Dr. Kamal Sharma (DIN: 00209430) as an Independent Director of the Company, not liable to retire by rotation, for a second term of five consecutive years from August 25, 2025 to August 24, 2030.MoreLess
    1 for0 against
  • 9. Re-appointment of Mr. Milind Sarwate (DIN: 00109854) as an Independent Director of the Company, not liable to retire by rotation, for a second term of five consecutive years from August 25, 2025 to August 24, 2030.MoreLess
    Against quant Mutual Fund
    • quant Mutual FundRelated to the re-appointment of Mr Milind Sarwate as an independent director. Compliant with the law. Governance concern: Combined position as the AC & NRC Chairperson is not in the best interest of corporate governance. Excessive time commitments.
    0 for1 against
  • Adoption of standalone and consolidated financial statements for the year ended 31 March 2025
    1 for0 against
  • Appointment of M/s BMP and Co. LLP , Practicing Company Secretaries (Firm Registration Number: L2017KR003200) as Secretarial Auditors of the Company, for a term of five (5) consecutive years, to hold office of the Secretarial Auditor for the Financial Year 2025-26 up to Financial Year 2029-30, on such remuneration, as may be mutually agreed between the Board of Directors of the Company and the Secretarial Auditors, from time to time.MoreLess
    Against Angel One Mutual Fund, Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund
    • Angel One Mutual FundTransparency Concern: Previous auditors’ remuneration not disclosed; thus, it is difficult to ascertain any material change in the Audit fee.
    • Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual FundCompliant with law. No concern on the merits of proposed Auditors. Transparency Concern: Previous auditors’ remuneration not disclosed; thus, it is difficult to ascertain any material change in the Audit fee.
    1 for4 against
  • Approve payment of commission to non-executive Directors in case of no profits/ inadequate profits for three years from 1 April 2025, within the regulatory thresholds
    1 for0 against
  • Approve revision in remuneration to Rajaram Narayanan (DIN: 02977405), Managing Director and Chief Executive Officer, for two years from 1 April 2025
    1 for0 against
  • Payment of remuneration to Mr. Rajaram Narayanan (DIN: 02977405) as Managing Director and CEO of the Company for the period starting from April 1, 2025 to April 10, 2027.
    Against Angel One Mutual Fund, Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund
    • Angel One Mutual FundGovernance & Transparency concern: No absolute cap on the maximum number of options that may be granted.
    • Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual FundCompliant with law. No concern w.r.t quantum of proposed remuneration per se. Governance & Transparency concern: No absolute cap on the maximum no. of options that may be granted.
    1 for4 against
  • Ratification of remuneration of Rs. 1,50,000 plus applicable tax and re-imbursement of out-of-pocket expenses payable to M/s. Joshi Apte and Associates, Practicing Cost Accountants, (Firm Registration Number: 000240) who was appointed by the Board of Directors of the Company to conduct the audit of the cost records of the Company for the financial year ending March 31, 2026.MoreLess
    5 for0 against
  • Ratify remuneration of Rs. 150,000 payable to Joshi Apte & Associates as cost auditors for FY26
    1 for0 against
  • Re-appointment of Dr. Kamal Sharma (DIN: 00209430) as an Independent Director of the Company, not liable to retire by rotation, for a second term of five consecutive years from August 25, 2025 to August 24, 2030.MoreLess
    5 for0 against
  • Re-appointment of Mr. Milind Sarwate (DIN: 00109854) as an Independent Director of the Company, not liable to retire by rotation, for a second term of five consecutive years from August 25, 2025 to August 24, 2030.MoreLess
    Against Angel One Mutual Fund, Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund
    • Angel One Mutual FundGovernance Concern: Combined position as the Audit Committee & Nomination & Remuneration Committee Chairperson may not be in the best interest of Corporate governance since it might lead to concentration of power in the hands of a single individual. Excessive time commitments.
    • Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual FundCompliant with law. Governance Concern: Combined position as the AC & NRC Chairperson may not be in the best interest of Corporate governance since it might lead to concentration of power in the hands of a single individual. Excessive time commitments.
    1 for4 against
  • Reappoint BMP & Co. LLP as statutory auditors for five years from the conclusion of the 2024 AGM and authorize the board to fix their remuneration
    1 for0 against
  • Reappoint Dr. Kamal Sharma (DIN: 00209430) as Independent Director, for five years from 25 August 2025 and approve his continuation on the board since he has crossed the age of 75 years of age
    1 for0 against
  • Reappoint Milind Sarwate (DIN: 00109854) as Independent Director, for five years from 25 August 2025
    1 for0 against
  • Reappoint Neeraj Bharadwaj (DIN: 01314963) as Director, liable to retire by rotation
    1 for0 against
  • Reappoint Rajaram Narayanan (DIN: 02977405) as Director, liable to retire by rotation
    1 for0 against
  • To pay remuneration by way of commission to Non-Executive Directors (including Independent Directors) notwithstanding the profits / absence of profits / inadequacy of profits in the Company and such commission be paid to the said Non-Executive Directors (including Independent Directors) of the Company in such amounts or proportions and in such manner as may be determined by the Board of Directors of the Company for a period of three Financial Years i.e. FY 2025-26 to FY 2027-28 or such other time period as may be permitted under the Act.MoreLess
    Against Angel One Mutual Fund, Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund
    • Angel One Mutual FundGovernance & Transparency concern: No absolute cap on proposed payment of commission & past data is insufficient.
    • Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual FundCompliant with law. Governance & Transparency concern: No absolute cap on proposed payment of commission & past data is insufficient.
    1 for4 against
  • To re-appoint Mr. Neeraj Bharadwaj (DIN: 01314963), Non-Executive Director who retires by rotation and being eligible, offers himself for re-appointment.
    Against Angel One Mutual Fund, Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund
    • Angel One Mutual FundGovernance Concern: Low attendance at Audit Committee without any justification.
    • Bandhan Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual FundCompliant with Law. Governance Concern: Low attendance at Audit Committee without any justification.
    1 for4 against
  • To re-appoint Mr. Rajaram Narayanan (DIN: 02977405), Managing Director and Chief Executive Officer who retires by rotation and being eligible, offers himself for re-appointment.
    5 for0 against
  • To receive, consider, approve and adopt: a) The Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2025, together with the reports of Board of Directors and Auditors thereon and b) The Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2025, and the report of the Auditors thereon.MoreLess
    5 for0 against

Mutual fund votes, meeting of 19 Feb 2025, 7 fund houses

  • 1. Approval for appointment of Ms. Revati Parag Kasture (DIN: 07558973) as a Non- Executive Independent Director of the Company, not liable to retire by rotation, for a term of 5 (five) consecutive years with effect from December 17, 2024 up to December 16, 2029.MoreLess
    1 for0 against
  • Appoint Ms. Revati Kasture (DIN: 07558973) as Independent Director for five years from 17 December 2024
    1 for0 against
  • Approval for appointment of Ms. Revati Parag Kasture (DIN: 07558973) as a Non- Executive Independent Director of the Company, not liable to retire by rotation, for a term of 5 (five) consecutive years with effect from December 17, 2024 up to December 16, 2029.MoreLess
    5 for0 against

Each fund house counted once, from its own disclosure; the reasons are its own words.

Investor complaints and compliance

Quarter by quarter.

Investor complaints received and resolved, the company's own count

  • Received
  • Resolved

Open at the quarter's end

None open at any quarter's end.
The board is made up as the listing rules require
Yes
The board has a regular chairperson
Yes
The company has a risk management committee
Yes
The chair is related to the managing director
No
The filing has a part on fines and penalties
No
The filing has a part on tax disputes
No
There was a cyber security incident in the quarter
No

The company's own answers in its filing.